Navigation Links
BioElectronics' Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
Date:1/19/2012

FREDERICK, Md., Jan. 19, 2012 /PRNewswire/ -- BioElectronics Corporation. (OTC-PINK: BIEL), the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced the acceptance for publication of an article in the peer reviewed journal The Journal of Foot and Ankle Surgery. The article documents the clinical trial results of BioElectronics' study of its medical device on plantar fasciitis.

Plantar fasciitis, or heel pain, is a very common complaint which affects up to two million people in the United States yearly, in a multi-million dollar treatment market. Plantar fasciitis heel pain, with the current treatment options, can persist up to one or two years and can be extremely painful and debilitating. 

"With this published clinical trial, which was a placebo controlled, randomized and double blind study, BioElectronics is demonstrating that its patented pulsed radiofrequency electromagnetic field therapy medical device offers a rapid and economical resolution of the heel pain, and consequently is a significant advancement over current treatment options," said Ian Rawe, PhD, BioElectronics Director of Clinical Research. "The publication of these results will help introduce to the medical community a drug-free treatment featuring our unique medical device as an orthopedic pain therapy. We anticipate strong interest which will lead to expanded clinical study on a variety of orthopedic conditions." 

BioElectronics is currently conducting a second clinical study on plantar fasciitis using its revolutionary 'Smart Insole,' which provides a simple, 24-hour treatment option. With this new study, BioElectronics anticipates that it is moving toward making its therapy the treatment of choice in people suffering from plantar fasciitis.

About BioElectronics Corporation

BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:
Paul Knopick
E & E Communications
(949) 707-5365
pknopick@eandecommunications.com

 

 

 


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
2. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
3. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
4. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
5. BioElectronics Announces Major Clinical Trials
6. Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
7. Incisive Surgical Announces Breakthrough Peer Review Clinical Study
8. Public Policy Staffing Study Offers Benchmark Opportunity for Bio-Pharma and Medical Device Companies
9. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
11. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):